Shots:

• The P-III ADAURA study involves assessing of Tagrisso (80 mg- qd) vs PBO in the adjuvant treatment of 682 patients with stage IB- II- and IIIA EGFRm NSCLC with complete tumor resection & adjuvant CT as an option across 20+ countries
• Results: in 1EPs of DFS & DFS in IIT population (83% & 79%) reduction in risk of disease recurrence or death- @2yrs. the patient remained alive & disease-free (89% vs 53%)- presented at ASCO on May 31- 2020. Multiple presentations during ASCO20 showcased AstraZeneca’s leadership in lung cancer across early- and late-stage disease and reinforce the Company’s biomarker-driven approach
• Tagrisso (40 & 80mg) is a third-generation- irreversible EGFR-TKI with clinical activity against CNS metastases and has received approval as 1L treatment for EGFRm advanced NSCLC in many countries across the globe including US- EU- Japan- China

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca